Developer docs
API playgroundTry for free, no card

Search company profiles

Transcend Therapeutics

Full company profile

uuid0000vrg

Namestring
Transcend Therapeutics
Legal namestring
Transcend Therapeutics, Inc.
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Transcend Therapeutics is a clinical-stage biotechnology company founded in 2021 and headquartered in New York City, developing rapid-acting neuroplastogen treatments for neuropsychiatric diseases. The company's core asset is TSND-201 (methylone), an oral proprietary formulation that acts as a triple reuptake inhibitor and releaser of serotonin, norepinephrine, and dopamine, rapidly inducing BDNF-mediated neuroplasticity without hallucinogenic activity (no 5-HT2A receptor binding) and with compatibility for patients on SSRIs. TSND-201 is currently in Phase 3 development for PTSD following FDA Breakthrough Therapy Designation (July 2025) and a Commissioner's National Priority Voucher (April 2026), supported by positive Phase 2 IMPACT-1 data published in JAMA Psychiatry showing a -9.64 placebo-adjusted CAPS-5 improvement at Day 64.

The company's pipeline also targets Major Depressive Disorder and Generalized Anxiety Disorder, with next-generation prodrug candidates classified as new chemical entities in preclinical development. Leadership includes Blake Mandell (Co-founder/CEO, ex-BCG and AlleyCorp), Kevin Ryan (Co-founder/Chairman, AlleyCorp founder and MongoDB/Business Insider co-founder), Benjamin Kelmendi, MD (Co-founder/Chief Scientific Advisor, Yale), Martin Stogniew, PhD (Chief Development Officer, holder of 40 patents), and Amanda Jones, PharmD (SVP Clinical Development, former Axsome Therapeutics). The team is credited with contributions to 14 FDA approvals and $7 billion in M&A and public company value.

Transcend operates as a pre-revenue, clinical-stage company. Its $40 million Series A (February 2023) was co-led by Alpha Wave Global and Integrated Investment Partners, with the company emerging from stealth with approximately $42 million in total funding. A $1 million collaborative grant from the U.S. Department of Defense (September 2023) funded preclinical research with Yale University. On June 12, 2026, Otsuka America Inc. completed acquisition of Transcend for $700 million upfront plus up to $525 million in sales milestone payments (total up to $1.225 billion), making Transcend a wholly owned subsidiary of Otsuka Pharmaceutical. Post-acquisition, Transcend's commercial distribution will leverage Otsuka's established global pharmaceutical infrastructure.

Short descriptiontext

Transcend Therapeutics is a clinical-stage biotechnology company developing TSND-201 (methylone), a rapid-acting non-hallucinogenic neuroplastogen in Phase 3 trials for PTSD, targeting the 13 million Americans affected annually. Acquired by Otsuka Pharmaceutical in June 2026 for up to $1.225 billion.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neuropsychiatric drug development, PTSD therapeutics, clinical-stage biotechnology, rapid-acting neuroplastogens, CNS disorder treatments
Industry2 codes
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Neuropsychiatric Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Revenue
TypeOne Time License
Description

Pre-commercial stage. Transcend Therapeutics was acquired by Otsuka Pharmaceutical in June 2026 for $700 million upfront plus up to $525 million in milestone payments. Revenue will come from future sales of TSND-201 (methylone) if approved by FDA for PTSD and other indications.

pulse2.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Transcend Therapeutics is developing TSND-201 (methylone), a proprietary oral rapid-acting neuroplastogen for the treatment of Post-Traumatic Stress Disorder (PTSD), Major Depressive Disorder (MDD), and other CNS indications. The compound acts as a triple monoamine reuptake inhibitor and releaser that induces neuroplasticity without hallucinogenic effects. The company is also advancing a pipeline of next-generation prodrug analogs classified as new chemical entities for broader neuropsychiatric indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • TSND-201 demonstrated -9.64 placebo-adjusted CAPS-5 improvement at Day 64 (p=0.011), meeting the primary endpoint of the IMPACT-1 Phase 2 study.
+4 more records
Product overview1 text field

Transcend Therapeutics is a clinical-stage biotechnology company developing a portfolio of rapid-acting neuroplastogen treatments for neuropsychiatric diseases. The company's core product is TSND-201 (methylone), an oral neuroplastogen currently in Phase 3 development for PTSD with FDA Breakthrough Therapy designation. TSND-201 works by enhancing neuroplasticity through monoamine release without hallucinogenic effects. The company is also developing next-generation analogs (novel prodrugs) for broader CNS disorders including Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD). Transcend operated as an independent company from 2021 until its acquisition by Otsuka Pharmaceutical in June 2026.

Product and service2 records
1TSND-201 (Methylone)
CategoryCore pharmaceutical product
Description

TSND-201 is a proprietary oral formulation of methylone, a rapid-acting neuroplastogen being developed for the treatment of Post-Traumatic Stress Disorder (PTSD). It acts on monoamine transporters (serotonin, norepinephrine, dopamine) and induces neuroplasticity without hallucinogenic effects (no 5-HT2A activity). It is currently in Phase 3 clinical trials for PTSD with Breakthrough Therapy designation from the FDA, and is being evaluated for Major Depressive Disorder and other CNS indications.

2Next-Generation Prodrug Analogs
CategoryPipeline pharmaceutical products
Description

Novel prodrug candidates classified as new chemical entities being developed to further improve the balance of efficacy, safety, and tolerability compared to TSND-201. Currently in preclinical stage with non-clinical studies underway in preparation for IND application for CNS disorders including generalized anxiety disorder and other indications.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-21
Description

Collaborative research grant with Yale University funded by the U.S. Department of Defense ($1 million over 3 years). Yale researchers are conducting preclinical studies using state-of-the-art microscopy and behavioral methods to understand the neurobiological mechanism underlying methylone's rapid-acting, long-lasting effects in PTSD. Co-founded by Dr. Benjamin Kelmendi, co-director of the Yale Program for Psychedelic Science.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Most direct competitor: developing MDMA-assisted therapy for PTSD, the same lead indication as Transcend's TSND-201. Comparability is high in target indication and patient population, though Lykos uses a classical psychedelic with hallucinogenic effects, whereas TSND-201 is non-hallucinogenic.

TypeDirect peer
Description

Clinical-stage company developing psilocybin therapy for treatment-resistant depression, with an adjacent psychiatric focus to Transcend's MDD/anxiety pipeline. Both operate in the psychedelic/neuroplastogen therapeutic category and pursue regulatory pathways in CNS.

TypeDirect peer
Description

Clinical-stage company developing mebufotenin and other psychedelic compounds for treatment-resistant depression. Comparability in mechanism class (rapid-acting tryptamine/serotonergic) and CNS indication strategy is high.

4MindMed
TypeDirect peer
Description

Clinical-stage company developing psychedelic-inspired medicines (e.g., MM-120, MDMA derivatives) for anxiety, ADHD, and other CNS disorders. Operates in the same rapid-acting neuroplastogen category as Transcend with overlapping target indications.

5Atai Life Sciences
TypeDirect peer
Description

Holding company with multiple subsidiaries developing psychedelic-based therapies for mental health (depression, PTSD, anxiety). Portfolio approach is comparable to Transcend's emerging prodrug platform strategy, both addressing the same psychedelic therapeutics market.

TypeBroad incumbent
Description

Commercial-stage CNS company with Auvelity (dextromethorphan-bupropion) approved for major depressive disorder. Comparable as a focused CNS innovator with rapid-acting mechanisms and overlapping MDD target; SVP Clinical Development Amanda Jones led Auvelity's development at Axsome before joining Transcend.

TypeBroad incumbent
Description

Commercial-stage CNS company with Zurzuvae approved for postpartum depression. Comparable as an established CNS-focused biopharma developing novel mechanisms for depression and other neuropsychiatric indications served by Transcend.

8Johnson & Johnson (Janssen)
TypeBroad incumbent
Description

Large pharmaceutical company marketing Spravato (esketamine) for treatment-resistant depression — the only FDA-approved rapid-acting antidepressant and a direct competitor to TSND-201 in mechanism class and indication. Brings established CNS commercial infrastructure.

TypeEmerging player
Description

Clinical-stage company developing non-hallucinogenic neuroplastogens (e.g., DLX-1) for depression, PTSD, and other CNS disorders. Highly comparable mechanism and indication strategy to Transcend's TSND-201 and next-generation prodrug platform.

TypeBroad incumbent
Description

Commercial-stage CNS company with Caplyta (lumateperone) approved for schizophrenia and bipolar depression. Comparable as a focused CNS innovator with overlapping psychiatry indications and demonstrated ability to take novel CNS mechanisms through FDA approval.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Transcend Therapeutics

Neuropsychiatric Therapeuticstranscendtherapeutics.com

Transcend Therapeutics is a clinical-stage biotechnology company developing TSND-201 (methylone), a rapid-acting non-hallucinogenic neuroplastogen in Phase 3 trials for PTSD, targeting the 13 million Americans affected annually. Acquired by Otsuka Pharmaceutical in June 2026 for up to $1.225 billion.

What Transcend Therapeutics does

Transcend Therapeutics is a clinical-stage biotechnology company founded in 2021 and headquartered in New York City, developing rapid-acting neuroplastogen treatments for neuropsychiatric diseases. The company's core asset is TSND-201 (methylone), an oral proprietary formulation that acts as a triple reuptake inhibitor and releaser of serotonin, norepinephrine, and dopamine, rapidly inducing BDNF-mediated neuroplasticity without hallucinogenic activity (no 5-HT2A receptor binding) and with compatibility for patients on SSRIs. TSND-201 is currently in Phase 3 development for PTSD following FDA Breakthrough Therapy Designation (July 2025) and a Commissioner's National Priority Voucher (April 2026), supported by positive Phase 2 IMPACT-1 data published in JAMA Psychiatry showing a -9.64 placebo-adjusted CAPS-5 improvement at Day 64.

The company's pipeline also targets Major Depressive Disorder and Generalized Anxiety Disorder, with next-generation prodrug candidates classified as new chemical entities in preclinical development. Leadership includes Blake Mandell (Co-founder/CEO, ex-BCG and AlleyCorp), Kevin Ryan (Co-founder/Chairman, AlleyCorp founder and MongoDB/Business Insider co-founder), Benjamin Kelmendi, MD (Co-founder/Chief Scientific Advisor, Yale), Martin Stogniew, PhD (Chief Development Officer, holder of 40 patents), and Amanda Jones, PharmD (SVP Clinical Development, former Axsome Therapeutics). The team is credited with contributions to 14 FDA approvals and $7 billion in M&A and public company value.

Transcend operates as a pre-revenue, clinical-stage company. Its $40 million Series A (February 2023) was co-led by Alpha Wave Global and Integrated Investment Partners, with the company emerging from stealth with approximately $42 million in total funding. A $1 million collaborative grant from the U.S. Department of Defense (September 2023) funded preclinical research with Yale University. On June 12, 2026, Otsuka America Inc. completed acquisition of Transcend for $700 million upfront plus up to $525 million in sales milestone payments (total up to $1.225 billion), making Transcend a wholly owned subsidiary of Otsuka Pharmaceutical. Post-acquisition, Transcend's commercial distribution will leverage Otsuka's established global pharmaceutical infrastructure.

Transcend Therapeutics firmographics

Firmographics
Name
Transcend Therapeutics
Legal name
Transcend Therapeutics, Inc.
Website
https://transcendtherapeutics.com
Company type
Private
Founded year
2021
Operating status
Acquired
Headcount range
11–50 employees
Short description
Transcend Therapeutics is a clinical-stage biotechnology company developing TSND-201 (methylone), a rapid-acting non-hallucinogenic neuroplastogen in Phase 3 trials for PTSD, targeting the 13 million Americans affected annually. Acquired by Otsuka Pharmaceutical in June 2026 for up to $1.225 billion.
Ownership category
akta.pro rank

Transcend Therapeutics industry classification

Industry
Product category
Neuropsychiatric Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Neuropsychiatric drug development
  • PTSD therapeutics
  • Clinical-stage biotechnology
  • Rapid-acting neuroplastogens
  • CNS disorder treatments

Where Transcend Therapeutics is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Transcend Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Product Revenue: Pre-commercial stage. Transcend Therapeutics was acquired by Otsuka Pharmaceutical in June 2026 for $700 million upfront plus up to $525 million in milestone payments. Revenue will come from future sales of TSND-201 (methylone) if approved by FDA for PTSD and other indications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Transcend Therapeutics product offering

Product offering

Core offering

Transcend Therapeutics is developing TSND-201 (methylone), a proprietary oral rapid-acting neuroplastogen for the treatment of Post-Traumatic Stress Disorder (PTSD), Major Depressive Disorder (MDD), and other CNS indications. The compound acts as a triple monoamine reuptake inhibitor and releaser that induces neuroplasticity without hallucinogenic effects. The company is also advancing a pipeline of next-generation prodrug analogs classified as new chemical entities for broader neuropsychiatric indications.

Product overview

Transcend Therapeutics is a clinical-stage biotechnology company developing a portfolio of rapid-acting neuroplastogen treatments for neuropsychiatric diseases. The company's core product is TSND-201 (methylone), an oral neuroplastogen currently in Phase 3 development for PTSD with FDA Breakthrough Therapy designation. TSND-201 works by enhancing neuroplasticity through monoamine release without hallucinogenic effects. The company is also developing next-generation analogs (novel prodrugs) for broader CNS disorders including Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD). Transcend operated as an independent company from 2021 until its acquisition by Otsuka Pharmaceutical in June 2026.

Differentiator

Problem solved

Functional benefit

Products and services

  • TSND-201 (Methylone) TSND-201 is a proprietary oral formulation of methylone, a rapid-acting neuroplastogen being developed for the treatment of Post-Traumatic Stress Disorder (PTSD). It acts on monoamine transporters (serotonin, norepinephrine, dopamine) and induces neuroplasticity without hallucinogenic effects (no 5-HT2A activity). It is currently in Phase 3 clinical trials for PTSD with Breakthrough Therapy designation from the FDA, and is being evaluated for Major Depressive Disorder and other CNS indications.
  • Next-Generation Prodrug Analogs Novel prodrug candidates classified as new chemical entities being developed to further improve the balance of efficacy, safety, and tolerability compared to TSND-201. Currently in preclinical stage with non-clinical studies underway in preparation for IND application for CNS disorders including generalized anxiety disorder and other indications.

Quantifiable outcome

  • TSND-201 demonstrated -9.64 placebo-adjusted CAPS-5 improvement at Day 64 (p=0.011), meeting the primary endpoint of the IMPACT-1 Phase 2 study.
  • +4 more outcomes

Companies that use Transcend Therapeutics

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Transcend Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Transcend Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Yale UniversitycoreStrategic or Co-development Partner · 21 September 2023Collaborative research grant with Yale University funded by the U.S. Department of Defense ($1 million over 3 years). Yale researchers are conducting preclinical studies using state-of-the-art microscopy and behavioral methods to understand the neurobiological mechanism underlying methylone's rapid-acting, long-lasting effects in PTSD. Co-founded by Dr. Benjamin Kelmendi, co-director of the Yale Program for Psychedelic Science.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Transcend Therapeutics competitors and assessment

Company assessment

Direct peers

  • Lykos Therapeutics (MAPS Public Benefit Corporation): Most direct competitor: developing MDMA-assisted therapy for PTSD, the same lead indication as Transcend's TSND-201. Comparability is high in target indication and patient population, though Lykos uses a classical psychedelic with hallucinogenic effects, whereas TSND-201 is non-hallucinogenic.
  • Compass Pathways: Clinical-stage company developing psilocybin therapy for treatment-resistant depression, with an adjacent psychiatric focus to Transcend's MDD/anxiety pipeline. Both operate in the psychedelic/neuroplastogen therapeutic category and pursue regulatory pathways in CNS.
  • GH Research: Clinical-stage company developing mebufotenin and other psychedelic compounds for treatment-resistant depression. Comparability in mechanism class (rapid-acting tryptamine/serotonergic) and CNS indication strategy is high.
  • MindMed: Clinical-stage company developing psychedelic-inspired medicines (e.g., MM-120, MDMA derivatives) for anxiety, ADHD, and other CNS disorders. Operates in the same rapid-acting neuroplastogen category as Transcend with overlapping target indications.
  • Atai Life Sciences: Holding company with multiple subsidiaries developing psychedelic-based therapies for mental health (depression, PTSD, anxiety). Portfolio approach is comparable to Transcend's emerging prodrug platform strategy, both addressing the same psychedelic therapeutics market.

Broad incumbents

  • Axsome Therapeutics: Commercial-stage CNS company with Auvelity (dextromethorphan-bupropion) approved for major depressive disorder. Comparable as a focused CNS innovator with rapid-acting mechanisms and overlapping MDD target; SVP Clinical Development Amanda Jones led Auvelity's development at Axsome before joining Transcend.
  • Sage Therapeutics: Commercial-stage CNS company with Zurzuvae approved for postpartum depression. Comparable as an established CNS-focused biopharma developing novel mechanisms for depression and other neuropsychiatric indications served by Transcend.
  • Johnson & Johnson (Janssen): Large pharmaceutical company marketing Spravato (esketamine) for treatment-resistant depression — the only FDA-approved rapid-acting antidepressant and a direct competitor to TSND-201 in mechanism class and indication. Brings established CNS commercial infrastructure.
  • Intra-Cellular Therapies: Commercial-stage CNS company with Caplyta (lumateperone) approved for schizophrenia and bipolar depression. Comparable as a focused CNS innovator with overlapping psychiatry indications and demonstrated ability to take novel CNS mechanisms through FDA approval.

Emerging players

  • Delix Therapeutics: Clinical-stage company developing non-hallucinogenic neuroplastogens (e.g., DLX-1) for depression, PTSD, and other CNS disorders. Highly comparable mechanism and indication strategy to Transcend's TSND-201 and next-generation prodrug platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Transcend Therapeutics social profiles

Digital presence

Transcend Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Transcend Therapeutics leadership team

Management profile

Number of profiles

Profiles5 records

Transcend Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Transcend Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Transcend Therapeutics

What does Transcend Therapeutics do?

Transcend Therapeutics is developing TSND-201 (methylone), a proprietary oral rapid-acting neuroplastogen for the treatment of Post-Traumatic Stress Disorder (PTSD), Major Depressive Disorder (MDD), and other CNS indications. The compound acts as a triple monoamine reuptake inhibitor and releaser that induces neuroplasticity without hallucinogenic effects. The company is also advancing a pipeline of next-generation prodrug analogs classified as new chemical entities for broader neuropsychiatric indications.

Is Transcend Therapeutics a public or private company?

Transcend Therapeutics is a private company. It is classified as corporate owned and is currently acquired.

When was Transcend Therapeutics founded?

Transcend Therapeutics was founded in 2021. It employs 11 to 50 people.

Where is Transcend Therapeutics based?

Transcend Therapeutics is headquartered in New York, United States, in the North America region.

How does Transcend Therapeutics make money?

One revenue line is on record: pharmaceutical Product Revenue.

Who are Transcend Therapeutics's main competitors?

Direct peers on record are Lykos Therapeutics (MAPS Public Benefit Corporation), Compass Pathways, GH Research, MindMed and Atai Life Sciences. Broad incumbents are Axsome Therapeutics, Sage Therapeutics, Johnson & Johnson (Janssen) and Intra-Cellular Therapies. Delix Therapeutics is listed as an emerging player.

Does Transcend Therapeutics have an API?

No public API is recorded for Transcend Therapeutics.

What industry is Transcend Therapeutics in?

Transcend Therapeutics's product category is Neuropsychiatric Therapeutics. Its primary akta.pro industry code is HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinanzNachrichten.deOtsuka und AbbVie kaufen sich in die Psychedelika-Medizin ein: Was das für die Infrastruktur-Frage bedeutetAbbVie agreed to pay up to $1.2 billion for Gilgamesh's psychedelic drug candidate, and Otsuka paid $700 million for Transcend's MDMA analog. These acquisitions signal growing interest from major pharma firms in psychedelic therapeutics. Emyria, a clinical infrastructure operator, stands to benefit from increased demand for treatment facilities.The Blog of Author Tim FerrissThe Tim Ferriss Show Transcripts: How to Spot 10-Year Trends and Build Billion-Dollar Companies — Kevin Ryan of DoubleClick, MongoDB, Business Insider, and Many More (#884)Kevin Ryan, co-founder of DoubleClick, MongoDB, and Business Insider, discusses spotting 10-year trends and building billion-dollar companies. He cites DoubleClick, MongoDB, and psychedelics as successful bets, and notes Gilt Groupe's commoditization. He also mentions upcoming investments in deep tech and nuclear energy.PR NewswireTranscend Public Benefit Corporation Launches $20 Million Philanthropic Initiative for Research of and Access to Psychedelic Mental Health CareTranscend Public Benefit Corporation is launching a $20 million philanthropic initiative over the next year to support nonprofit organizations advancing mental health treatment access, infrastructure, and research in the psychedelic therapeutics space. The initiative grew out of Transcend Therapeutics' work in rapid-acting mental health treatment R&D and the company's recent acquisition, with founders directing a portion of exit proceeds back to the field. Funding priorities include survivors of sexual trauma, substance use and addiction, end of life care, depression, LGBTQ+, and other underserved populations whose needs have outpaced current infrastructure.YahooTranscend Public Benefit Corporation Launches $20 Million Philanthropic Initiative for Research of and Access to Psychedelic Mental Health CareTranscend Public Benefit Corporation is launching a philanthropic initiative directing approximately $20 million over the next year to nonprofit organizations advancing mental health treatment access, field infrastructure, and research in psychedelic therapeutics. The funding prioritizes underserved populations, including survivors of sexual trauma, substance use, and end-of-life care, and is not an open call for proposals.BioSpaceOtsuka Completes Acquisition of Transcend Therapeutics to Advance Next-Generation Neuropsychiatric TreatmentsOtsuka America, Inc., a subsidiary of Otsuka Pharmaceutical Co., Ltd., has completed its acquisition of clinical-stage biotechnology company Transcend Therapeutics, Inc. for $700 million upfront with up to $525 million in additional contingent consideration based on future sales. The acquisition gives Otsuka access to Transcend's lead candidate TSND-201 (methylone), a rapid-acting neuroplastogen for PTSD treatment that has received FDA Breakthrough Therapy designation and is currently in Phase 3 trials. The deal expands Otsuka's neuropsychiatric portfolio at a time when more than 13 million Americans are affected by PTSD annually, with no new treatments approved in over 25 years.Pulse 2.0Otsuka Completes $700 Million Acquisition Of Transcend TherapeuticsOtsuka America, a subsidiary of Otsuka Pharmaceutical, has completed its acquisition of Transcend Therapeutics, a clinical-stage biotechnology company, for $700 million upfront with potential additional payments of up to $525 million tied to future sales milestones. Transcend's lead investigational candidate TSND-201 (methylone) is a rapid-acting neuroplastogen in development for post-traumatic stress disorder, which has received Breakthrough Therapy designation from the FDA and is currently undergoing Phase 3 trials. The transaction is intended to accelerate the development and commercialization of new treatment options for patients with significant unmet needs, with no new PTSD treatments having been approved in more than 25 years.Pulse 2.0Transcend Therapeutics: Otsuka Pharmaceutical Completes Acquisition To Advance PTSD Treatment DevelopmentOtsuka America, a subsidiary of Otsuka Pharmaceutical, has completed its acquisition of Transcend Therapeutics, making it a wholly owned subsidiary. Transcend's lead program TSND-201 (methylone) for PTSD treatment received FDA Breakthrough Therapy Designation in 2025 and is currently in Phase 3 clinical trials. Otsuka stated the acquisition strengthens its commitment to addressing unmet needs in mental health and positions the combined organizations to accelerate development of innovative neuropsychiatric therapies.citybizOtsuka Completes $700M Acquisition of Transcend Therapeutics to Expand PTSD PipelineOtsuka America, Inc., a subsidiary of Otsuka Pharmaceutical Co., Ltd., has completed its acquisition of Transcend Therapeutics, a clinical-stage biotechnology company developing TSND-201 (methylone), a rapid-acting treatment for post-traumatic stress disorder, for $700 million upfront with up to $525 million in additional contingent payments. Transcend, founded in 2021 and headquartered in New York City, will operate as a wholly owned subsidiary of Otsuka America following the close of the transaction. The deal strengthens Otsuka's position in neuropsychiatric therapeutics and gives it access to a Phase 3-stage PTSD asset that has received Breakthrough Therapy designation from the FDA, entering a market where no new treatments have been approved in over 25 years.PR NewswireTranscend Therapeutics Announces Completion of Acquisition by Otsuka PharmaceuticalTranscend Therapeutics announced the completion of its acquisition by Otsuka America Inc., a subsidiary of Otsuka Pharmaceutical Co., Ltd., making Transcend a wholly owned subsidiary of Otsuka. The acquisition, originally announced on March 27, 2026, will provide Transcend with greater resources to advance TSND-201, its rapid-acting neuroplastogen for PTSD treatment, which is currently in Phase 3 clinical development and received FDA Breakthrough Therapy Designation in 2025. The deal supports Transcend's mission to develop treatments for neuropsychiatric diseases for patients who have not benefited from existing therapies.Business Wire BlogOtsuka Completes Acquisition of Transcend Therapeutics to Advance Next-Generation Neuropsychiatric TreatmentsOtsuka completed its acquisition of Transcend Therapeutics, paying $700 million at closing with up to $525 million in contingent consideration. Transcend's lead candidate TSND-201, a rapid-acting treatment for PTSD, showed favorable Phase 2 results and is in Phase 3. The deal aims to accelerate development of new neuropsychiatric therapies.